Variable prostaglandin E2 resistance in fibroblasts from patients with usual interstitial pneumonia

American Journal of Respiratory and Critical Care Medicine

Volumn 177, Issue 1, 2008, Pages 66-74

  Huang, Steven K ^a   Wettlaufer, Scott H ^a   Hogaboam, Cory M ^a   Flaherty, Kevin R ^a   Martinez, Fernando J ^a   Myers, Jeffrey L ^a   Colby, Thomas V ^b   Travis, William D ^c   Toews, Galen B ^a   Peters Golden, Marc ^a,d  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b MAYO CLINIC   (United States)

^c MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^d Division of Pulmonary and Critical Care Medicine   (United States)

Author keywords

cAMP; Collagen; Idiopathic pulmonary fibrosis; Nonspecific interstitial pneumonia; Proliferation

Indexed keywords

PROSTAGLANDIN E2; PROSTANOID RECEPTOR; COLLAGEN TYPE 1; CYCLIC AMP;

ADULT; AGED; ARTICLE; CELL PROLIFERATION; CLINICAL ARTICLE; COLLAGEN SYNTHESIS; CONTROLLED STUDY; DIFFUSE PARENCHYMAL LUNG DISEASE; DRUG INHIBITION; DRUG MECHANISM; FEMALE; FIBROBLAST; HUMAN; HUMAN TISSUE; IN VITRO STUDY; INTERSTITIAL PNEUMONIA; LUNG DISEASE; LUNG FUNCTION; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; CELL DIVISION; CELL LINE; DRUG EFFECT; DRUG RESISTANCE; INTERSTITIAL LUNG DISEASE; LUNG; LUNG FIBROSIS; METABOLISM; MIDDLE AGED; PATHOLOGY;

ADULT; AGED; AGED, 80 AND OVER; CELL DIVISION; CELL LINE; COLLAGEN TYPE I; CYCLIC AMP; DINOPROSTONE; DRUG RESISTANCE; FEMALE; FIBROBLASTS; HUMANS; LUNG; LUNG DISEASES, INTERSTITIAL; MALE; MIDDLE AGED; PULMONARY FIBROSIS;

EID: 37849050983     PISSN: 1073449X     EISSN: 15354970     Source Type: Journal    
DOI: 10.1164/rccm.200706-963OC     Document Type: Article

References (40)

1. American Thoracic Society; European Respiratory Society. American Thoracic Society/European Respiratory Society international multidisciplinary consensus classification of the idiopathic interstitial pneumonias. Am J Respir Crit Care Med 2002;165:277-304.
2. Katzenstein AL, Myers JL. Idiopathic pulmonary fibrosis: clinical relevance of pathologic classification. Am J Respir Crit Care Med 1998;157:1301-1315.
3. Bjoraker JA, Ryu JH, Edwin MK, Myers JL, Tazelaar HD, Schroeder DR, Offord KP. Prognostic significance of histopathologic subsets in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 1998;157:199-203.
4. Myers JL, Katzenstein AL. Epithelial necrosis and alveolar collapse in the pathogenesis of usual interstitial pneumonia. Chest 1988;94:1309-1311.
5. Kuhn C III, Boldt J, King TE Jr, Crouch E, Vartio T, McDonald JA. An immunohistochemical study of architectural remodeling and connective tissue synthesis in pulmonary fibrosis. Am Rev Respir Dis 1989;140:1693-1703.
6. Kitaichi M. Pathologic features and the classification of interstitial pneumonia of unknown etiology. Bull Chest Dis Res Inst Kyoto Univ 1990;23:1-18.
7. Flaherty KR, Travis WD, Colby TV, Toews GB, Kazerooni EA, Gross BH, Jain A, Strawderman RL, Flint A, Lynch JP, et al. Histopathologic variability in usual and nonspecific interstitial pneumonias. Am J Respir Crit Care Med 2001;164:1722-1727.
8. Flaherty KR, Toews GB, Travis WD, Colby TV, Kazerooni EA, Gross BH, Jain A, Strawderman RL III, Paine R, Flint A, et al. Clinical significance of histological classification of idiopathic interstitial pneumonia. Eur Respir J 2002;19:275-283.
9. Kuhn C, McDonald JA. The roles of the myofibroblast in idiopathic pulmonary fibrosis: ultrastructural and immunohistochemical features of sites of active extracellular matrix synthesis. Am J Pathol 1991;138:1257-1265.
10. Selman M, King TE, Pardo A. Idiopathic pulmonary fibrosis: prevailing and evolving hypotheses about its pathogenesis and implications for therapy. Ann Intern Med 2001;134:136-151.
11. Martin P. Wound healing - aiming for perfect skin regeneration. Science 1997;276:75-81.
12. Lorena D, Uchio K, Costa AM, Desmouliere A. Normal scarring: importance of myofibroblasts. Wound Repair Regen 2002;10:86-92.
13. Kaminski N, Allard JD, Pittet JF, Zuo F, Griffiths MJ, Morris D, Huang X, Sheppard D, Heller RA. Global analysis of gene expression in pulmonary fibrosis reveals distinct programs regulating lung inflammation and fibrosis. Proc Natl Acad Sci USA 2000;97:1778-1783.
14. Ignotz RA, Massague J. Transforming growth factor-β stimulates the expression of fibronectin and collagen and their incorporation into the extracellular matrix. J Biol Chem 1986;261:4337-4345.
15. Border WA, Noble NA. Transforming growth factor β in tissue fibrosis. N Engl J Med 1994;331:1286-1292.
16. Wilborn J, Crofford LJ, Burdick MD, Kunkel SL, Strieter RM, Peters-Golden M. Cultured lung fibroblasts isolated from patients with idiopathic pulmonary fibrosis have a diminished capacity to synthesize prostaglandin E2 and to express cyclooxygenase-2. J Clin Invest 1995;95:1861-1868.
17. Peters-Golden M. When defenses against fibroproliferation fail: spotlight on an axis of prophylaxis. Am J Respir Crit Care Med 2003;168:1141-1142.
18. 2 production in normal and fibrotic lung fibroblasts: potential implications for the evolution of the inflammatory process. Am J Respir Cell Mol Biol 2000;22:628-634.
19. Keerthisingam CB, Jenkins RG, Harrison NK, Hernandez-Rodriguez NA, Booth H, Laurent GJ, Hart SL, Foster ML, McAnulty RJ. Cyclooxygenase-2 deficiency results in a loss of the anti-proliferative response to transforming growth factor-β in human fibrotic lung fibroblasts and promotes bleomycin-induced pulmonary fibrosis in mice. Am J Pathol 2001;158:1411-1422.
20. Kohyama T, Ertl RF, Valenti V, Spurzem J, Kawamoto M, Nakamura Y, Veys T, Allegra L, Romberger D, Rennard SI. Prostaglandin E(2) inhibits fibroblast chemotaxis. Am J Physiol Lung Cell Mol Physiol 2001;281:L1257-L1263.
21. 2 inhibits fibroblast migration by E-prostanoid 2 receptor-mediated increase in PTEN activity. Am J Respir Cell Mol Biol 2005;32:135-141.
22. Elias JA, Rossman MD, Zurier RB, Daniele RP. Human alveolar macrophage inhibition of lung fibroblast growth: a prostaglandin-dependent process. Am Rev Respir Dis 1985;131:94-99.
23. Bitterman PB, Wewers MD, Rennard SI, Adelberg S, Crystal RG. Modulation of alveolar macrophage-driven fibroblast proliferation by alternative macrophage mediators. J Clin Invest 1986;77:700-708.
24. 2. Biochim Biophys Acta 1992;1135:67-72.
25. Fine A, Poliks CF, Donahue LP, Smith BD, Goldstein RH. The differential effect of prostaglandin E2 on transforming growth factor-β and insulin-induced collagen formation in lung fibroblasts. J Biol Chem 1989;264:16988-16991.
26. 2 inhibits fibroblast to myofibroblast transition via E. prostanoid receptor 2 signaling and cyclic adenosine monophosphate elevation. Am J Respir Cell Mol Biol 2003;29:537-544.
27. Narumiya S, Sugimoto Y, Ushikubi F. Prostanoid receptors: structures, properties, and functions. Physiol Rev 1999;79:1193-1226.
28. 2 regulated expression of type I collagen α1, lysyl oxidase, and cyclooxygenase-1 genes in human embryo lung fibroblasts. J Cell Biochem 1998;71:254-263.
29. Huang, S. K., S. H. Wettlaufer, C. M. Hogaboam, D. M. Aronoff, and M. Peters-Golden. Prostaglandin E2 inhibits collagen expression and proliferation in patient-derived normal lung fibroblasts via E prostanoid 2 receptor and cAMP signaling. Am J Physiol Lung Cell Mol Physiol 2006;292:L405-L413.
30. 2 inhibition of proliferation and collagen synthesis is diminished in fibroblasts from patients with idiopathic interstitial pneumonia [abstract]. Am J Respir Crit Care Med 2007;175:A734.
31. Hogaboam CM, Carpenter KJ, Evanoff H, Kunkel SL. Approaches to evaluation of fibrogenic pathways in surgical lung biopsy specimens. Methods Mol Med 2005;117:209-221.
32. Rolfe MW, Kunkel SL, Standiford TJ, Orringer MB, Phan SH, Evanoff HL, Burdick MD, Strieter RM. Expression and regulation of human pulmonary fibroblast-derived monocyte chemotactic peptide-1. Am J Physiol 1992;263:L536-L545.
33. Mio T, Nagai S, Kitaichi M, Kawatani A, Izumi T. Proliferative characteristics of fibroblast lines derived from open lung biopsy specimens of patients with IPF (UIP). Chest 1992;102:832-837.
34. Shoda H, Yokoyama A, Nishino R, Nakashima T, Ishikawa N, Haruta Y, Hattori N, Naka T, Kohno N.. Overproduction of collagen and diminished SOCS1 expression are causally linked in fibroblasts from idiopathic pulmonary fibrosis. Biochem Biophys Res Commun 2006;353:1004-1010.
35. Jordana M, Schulman J, McSharry C, Irving LB, Newhouse MT, Jordana G, Gauldie J. Heterogeneous proliferative characteristics of human adult lung fibroblast lines and clonally derived fibroblasts from control and fibrotic tissue. Am Rev Respir Dis 1988;137:579-584.
36. 2. J Immunol 2005;174:5644-5649.
37. Liu X, Sun SQ, Ostrom RS. Fibrotic lung fibroblasts show blunted inhibition by cAMP due to deficient cAMP response element-binding protein phosphorylation. J Pharmacol Exp Ther 2005;315:678-687.
38. Hodges RJ, Jenkins RG, Wheeler-Jones CP, Copeman DM, Bottoms SE, Bellingan GJ, Nanthakumar CB, Laurent GJ, Hart SL, Foster ML, et al. Severity of lung injury in cyclooxygenase-2-deficient mice is dependent on reduced prostaglandin E(2) production. Am J Pathol 2004;165:1663-1676.
39. Stratton R, Shiwen X, Martini G, Holmes A, Leask A, Haberberger T, Martin GR, Black CM, Abraham D. Iloprost suppresses connective tissue growth factor production in fibroblasts and in the skin of scleroderma patients. J Clin Invest 2001;108:241-250.
40. Stratton R, Rajkumar V, Ponticos M, Nichols B, Shiwen X, Black CM, Abraham DJ, Leask A. Prostacyclin derivatives prevent the fibrotic response to TGF-β by inhibiting the Ras/MEK/ERK pathway. FASEB J 2002;16:1949-1951.